Perspectives in Medicinal Chemistry
Synopsis: An open access, peer reviewed electronic journal that covers drug design in the form of commentaries and reviews which do not require disclosure of proprietary information.
Indexing: Pubmed, Pubmed Central, Embase, Google Scholar, CAS, DOAJ, OAIster
Processing time: Decision in 2 weeks for 90% of papers.
Latest news:
Bioactive and Structural Metabolites of Pseudomonas and Burkholderia Species Causal Agents of Cultivated Mushrooms Diseases
Anna Andolfi1, Alessio Cimmino1, Pietro Lo Cantore2, Nicola Sante Iacobellis2 and Antonio Evidente1
1Dipartimento di Scienze del Suolo, della Pianta, dell’Ambiente e delle Produzioni Animali, Università di Napoli Federico II, Via Università 100, 80055 Portici, Italy. 2Dipartimento di Biologia, Difesa e Bio- tecnologie Agro-Forestali, Università degli Studi della Basilicata, Viale dell’Ateneo Lucano 10, 85100 Potenza, Italy.
Abstract
Pseudomonas tolaasii, P. reactans and Burkholderia gladioli pv. agaricicola, are responsible of diseases on some species of cultivated mushrooms. The main bioactive metabolites produced by both Pseudomonas strains are the lipodepsipeptides (LDPs) tolaasin I and II and the so called White Line Inducing Principle (WLIP), respectively, LDPs which have been extensively studied for their role in the disease process and for their biological properties. In particular, their antimicrobial activity and the alteration of biological and model membranes (red blood cell and liposomes) was established. In the case of tolaasin I interaction with membranes was also related to the tridimensional structure in solution as determined by NMR combined with molecular dynamic calculation techniques. Recently, five news minor tolaasins, tolaasins A-E, were isolated from the culture filtrates of P. tolaasii and their chemical structure was determined by extensive use of NMR and MS spectroscopy. Furthermore, their antimicrobial activity was evaluated on target micro-organisms (fungi—including the cultivated mushrooms
Agaricus bisporus, Lentinus edodes, and Pleurotus spp.—chromista, yeast and bacteria). The Gram positive bacteria resulted the most sensible and a signifi cant structure-activity relationships was apparent. The isolation and structure determination of bioactive metabolites produced by B. gladioli pv. agaricicola are still in progress but preliminary results indicate their peptide nature. Furthermore, the exopolysaccharide (EPS) from the culture filtrates of B. gladioli pv. agaricicola, as well as the O-chain and lipid A, from the lipo-polysaccharide (LPS) of the three bacteria, were isolated and the structures determined.
Readers of this also read:
- Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
- The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy
- Small Family with Key Contacts: Par14 and Par17 Parvulin Proteins, Relatives of Pin1, Now Emerge in Biomedical Research
- Lunasin: A Novel Cancer Preventive Seed Peptide
- Derivatives of 5-Aminolevulinic Acid for Photodynamic Therapy
- 26/May/2009
Aminoglycosides: Molecular Insights on the Recognition of RNA and Aminoglycoside Mimics
- 28/Apr/2009
Perspectives on Using Physcomitrella Patens as an Alternative Production Platform for Thapsigargin and Other Terpenoid Drug Candidates
- 04/Mar/2009
Bioactive and Structural Metabolites of Pseudomonas and Burkholderia Species Causal Agents of Cultivated Mushrooms Diseases
- 09/May/2008
The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy
- 10/Apr/2008
Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
- 10/Apr/2008
Lunasin: A Novel Cancer Preventive Seed Peptide
- 25/Mar/2008
Effects of FK506 on Ca2+ Release Channels (Review)
- 18/Mar/2008
Small Family with Key Contacts: Par14 and Par17 Parvulin Proteins, Relatives of Pin1, Now Emerge in Biomedical Research
- 07/Mar/2008
Modifications of Antiepileptic Drugs for Improved Tolerability and Efficacy
- 14/Feb/2008
Exploratory Studies on Development of the Chemokine Receptor CXCR4 Antagonists Toward Downsizing
- 10/Feb/2008
The Role of Glucose Metabolism and Glucose-Associated Signalling in Cancer
- 18/Jan/2008
Chemical Chaperone and Inhibitor Discovery: Potential Treatments for Protein Conformational Diseases
- 11/Dec/2007
Derivatives of 5-Aminolevulinic Acid for Photodynamic Therapy
- 11/Dec/2007
The pKa Distribution of Drugs: Application to Drug Discovery
- 17/Sep/2007
FTY720 Story. Its Discovery and the Following Accelerated Development of Sphingosine 1-Phosphate Receptor Agonists as Immunomodulators Based on Reverse Pharmacology
- 06/Sep/2007
Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034
- 26/Jun/2007
Perspectives in Medicinal Chemistry
Yitzhak Tor, Editor in Chief
Submit a paper
 |
|
 |
YAHOO! BUZZ |
 |
DIGG |
 |
|
 |
MIXX |
 |
PERMALINK |
 |
GOOGLE BOOKMARKS |
 |
DELICIOUS |
 |
|
 |
NEWSVINE |
International Journal of Insect Science indexed by CABI - 13/Oct/2009
Interview with Biomarker Insights editorial board member Dr Paul Lampe - 13/Oct/2009
Perspectives in Medicinal Chemistry now indexed by Pubmed - 13/Oct/2009
Gene Regulation and Systems Biology now indexed by Pubmed - 13/Oct/2009
Interview with Clinical Medicine: Cardiology editorial board member Dr Francisco R. Breijo-Márquez - 12/Oct/2009
Articles published in week 41 (October 5 to 11) - 12/Oct/2009
Research profile on Clinical Medicine: Arthritis and Musculoskeletal Disorders editorial board member Dr Axel Finckh - 09/Oct/2009
Interview with Clinical Medicine: Oncology editorial board member Dr Daniela Bota - 08/Oct/2009
Interview with International Journal of Pain editorial board member Dr Raymond Tait - 08/Oct/2009
Interview with Evolutionary Bioinformatics editorial board member Dr John Hancock - 06/Oct/2009
Interview with Clinical Medicine: Circulatory, Respiratory and Pulmonary Medicine editorial board member Dr Lee Morrow - 05/Oct/2009
Articles Published in Week 40 (September 28 to October 2) - 05/Oct/2009
Open access articles published in September - 02/Oct/2009
Announcing Biomedical Engineering and Computational Biology - 30/Sep/2009
Announcing the Indian Journal of Clinical Medicine - 30/Sep/2009
Autism Insights launched - 29/Sep/2009
Newsletter summary (week 37, 2009) - 25/Sep/2009
Interview with Clinical Medicine: Cardiology editorial board member Dr Vernon Barnes - 12/Oct/2009
Interview with Cancer Informatics editorial board member Dr Grant Izmirlian - 22/Sep/2009
Chelation Therapy for Mercury Poisoning - 07/Aug/2009
Immune- and Pollution-mediated DNA Damage in Two Wild Mya arenaria Clam Populations - 05/Aug/2009
Capsaicin - the Hot and Spicy Diet Turned Mild and Effective by Glycosylation - 06/Jul/2009
Renal Toxicity of Mercuric Chloride at Different Time Intervals in Rats - 23/Jun/2009
Prolonged Treatment with Free Fatty Acids has Post Receptor Effect in Hepatic Insulin Resistance: Evidence that Fatty Acids, Oleate and Palmitate have Insignificant Effect on the Insulin Receptor Beta In Vivo and Ex Vivo Primary Hepatocytes - 12/Jun/2009
Quantitative Mass spectrometric Analysis of Ropivacaine and Bupivacaine in Authentic, Pharmaceutical and Spiked Human Plasma without Chromatographic Separation - 28/May/2009
A Novel Mechanism in Regulating the Alpha-Subunit of the Epithelial Sodium Channel (α ENaC) by the Alternatively Spliced Form α ENaC-b - 15/Apr/2009
A 20 Residues Motif Delineates the Furin Cleavage Site and its Physical Properties May Influence Viral Fusion - 08/Apr/2009
Poly(ADP-ribose) Preparation Using Anion-Exchange Column Chromatography - 08/Apr/2009
Micelle Enhanced Fluorimetric and Thin Layer Chromatography Densitometric Methods for the Determination of (±) Citalopram and its S – Enantiomer Escitalopram - 07/Apr/2009
Fast and Simple micro-RNA Northern Blots - 04/Mar/2009
Production of (2R,3S)-2-Benzamidomethyl-3-Hydroxybutanoates by Immobilized Plant Cells of Parthenocissus Tricuspidata - 06/Jan/2009
New Spectrofluorimetric Method with Enhanced Sensitivity for Determination of Paroxetine in Dosage Forms and Plasma - 18/Nov/2008
Use of a Combined Duplex PCR/Dot Blot Assay for more sensitive genetic characterization - 06/Nov/2008